Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPS NASDAQ:CVKD NASDAQ:RNTX NASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPSCapstone Therapeutics$1.25-2.3%$1.37$0.96▼$16.18$6.98M-0.811.14 million shs64,623 shsCVKDCadrenal Therapeutics$13.35-0.1%$12.13$8.74▼$22.90$27.37M0.9432,583 shs29,664 shsRNTXRein Therapeutics$1.15+3.6%$1.28$1.04▼$4.40$26.80M1.1359,553 shs158,703 shsTENXTenax Therapeutics$6.30+3.4%$6.00$3.25▼$7.89$28.73M1.4431,092 shs284,258 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPSCapstone Therapeutics0.00%+10.34%+3.23%-31.91%+127,999,900.00%CVKDCadrenal Therapeutics+1.60%-0.07%+5.36%+1.75%+30.85%RNTXRein Therapeutics-6.72%-17.16%-7.04%-38.33%+110,999,900.00%TENXTenax Therapeutics-0.33%+0.83%+2.01%+7.22%+59.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPSCapstone Therapeutics$1.25-2.3%$1.37$0.96▼$16.18$6.98M-0.811.14 million shs64,623 shsCVKDCadrenal Therapeutics$13.35-0.1%$12.13$8.74▼$22.90$27.37M0.9432,583 shs29,664 shsRNTXRein Therapeutics$1.15+3.6%$1.28$1.04▼$4.40$26.80M1.1359,553 shs158,703 shsTENXTenax Therapeutics$6.30+3.4%$6.00$3.25▼$7.89$28.73M1.4431,092 shs284,258 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPSCapstone Therapeutics0.00%+10.34%+3.23%-31.91%+127,999,900.00%CVKDCadrenal Therapeutics+1.60%-0.07%+5.36%+1.75%+30.85%RNTXRein Therapeutics-6.72%-17.16%-7.04%-38.33%+110,999,900.00%TENXTenax Therapeutics-0.33%+0.83%+2.01%+7.22%+59.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPSCapstone Therapeutics 0.00N/AN/AN/ACVKDCadrenal Therapeutics 3.00Buy$32.00139.70% UpsideRNTXRein Therapeutics 2.00HoldN/AN/ATENXTenax Therapeutics 3.20Buy$18.00185.71% UpsideCurrent Analyst Ratings BreakdownLatest CAPS, TENX, RNTX, and CVKD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025TENXTenax TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.008/19/2025RNTXRein TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/14/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $14.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPSCapstone Therapeutics$44.88M0.16N/AN/A($19.40) per share-0.06CVKDCadrenal TherapeuticsN/AN/AN/AN/A$4.17 per shareN/ARNTXRein TherapeuticsN/AN/A$0.43 per share2.66$0.43 per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$26.99 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPSCapstone Therapeutics-$2.56MN/A0.00∞N/AN/AN/AN/AN/ACVKDCadrenal Therapeutics-$10.65M-$8.88N/AN/AN/AN/A-265.37%-196.38%11/6/2025 (Estimated)RNTXRein Therapeutics-$62.88M-$2.69N/AN/AN/AN/A-141.11%-33.83%N/ATENXTenax Therapeutics-$17.60M-$0.92N/AN/AN/AN/A-31.34%-30.39%11/12/2025 (Estimated)Latest CAPS, TENX, RNTX, and CVKD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025Q2 2025CAPSCapstone TherapeuticsN/A-$0.13N/A-$0.13N/A$12.85 million8/14/2025Q2 2025RNTXRein Therapeutics-$0.22-$0.28-$0.06-$0.28N/AN/A8/13/2025Q2 2025TENXTenax Therapeutics-$0.50-$0.27+$0.23-$0.27N/AN/A8/11/2025Q2 2025CVKDCadrenal Therapeutics-$1.60-$1.87-$0.27-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPSCapstone TherapeuticsN/AN/AN/AN/AN/ACVKDCadrenal TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPSCapstone Therapeutics0.220.970.41CVKDCadrenal TherapeuticsN/A3.553.55RNTXRein TherapeuticsN/A0.860.86TENXTenax TherapeuticsN/A41.8941.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPSCapstone Therapeutics2.55%CVKDCadrenal Therapeutics7.92%RNTXRein Therapeutics90.89%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipCAPSCapstone Therapeutics42.80%CVKDCadrenal Therapeutics26.09%RNTXRein Therapeutics5.10%TENXTenax Therapeutics3.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPSCapstone Therapeutics385.58 million3.19 millionN/ACVKDCadrenal Therapeutics42.05 million1.51 millionNot OptionableRNTXRein Therapeutics923.31 million22.12 millionN/ATENXTenax Therapeutics94.56 million4.39 millionNot OptionableCAPS, TENX, RNTX, and CVKD HeadlinesRecent News About These CompaniesTenax announces EPO intention to grant patent for levosimendan in PH-HFpEFSeptember 16 at 12:12 PM | msn.comTenax Therapeutics Secures European Patent Protection for TNX-103 and Levosimendan Formulations Until December 2040September 16 at 7:30 AM | quiverquant.comQTenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEFSeptember 16 at 7:00 AM | globenewswire.comTenax Therapeutics, Inc. (NASDAQ:TENX) Receives Average Rating of "Buy" from AnalystsSeptember 13 at 3:17 AM | americanbankingnews.comTenax Therapeutics (NASDAQ:TENX) Coverage Initiated at Piper SandlerSeptember 10, 2025 | americanbankingnews.comTenax Therapeutics initiated with an Overweight at Piper SandlerSeptember 9, 2025 | msn.comPiper Sandler Initiates Coverage of Tenax Therapeutics (TENX) with Overweight RecommendationSeptember 9, 2025 | msn.comTenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025August 28, 2025 | globenewswire.comTenax Posts Wider Loss in Fiscal Q2August 14, 2025 | aol.comATenax Therapeutics reports Q2 EPS (27c), consensus (45c)August 14, 2025 | msn.comTenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comTENX Tenax Therapeutics, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comTenax Therapeutics Inc.May 9, 2025 | barrons.comTenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comTenax Therapeutics: Q4 Earnings SnapshotMarch 25, 2025 | timesunion.comTNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025These 4 Mid-Caps Just Announced Big Buyback PlansBy Leo Miller | September 9, 2025CAPS, TENX, RNTX, and CVKD Company DescriptionsCapstone Therapeutics NASDAQ:CAPS$1.25 -0.03 (-2.34%) As of 04:00 PM EasternCapstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.Cadrenal Therapeutics NASDAQ:CVKD$13.35 -0.01 (-0.07%) Closing price 03:59 PM EasternExtended Trading$13.20 -0.15 (-1.16%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Rein Therapeutics NASDAQ:RNTX$1.15 +0.04 (+3.60%) As of 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Tenax Therapeutics NASDAQ:TENX$6.30 +0.21 (+3.45%) Closing price 04:00 PM EasternExtended Trading$6.31 +0.01 (+0.22%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
